<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col></col>
<col></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Antiretrovirals</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.</paragraph>
<list listtype="unordered" stylecode="Disc">
<item>
<paragraph>Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">li</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">cal</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">P</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">harmacology (12.3)</linkhtml>]</content>
<content stylecode="italics">.</content>
</paragraph>
</item>
</list>
<list listtype="unordered" stylecode="Disc">
<item>
<paragraph>Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">l</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">cal</linkhtml>
</content>
<content stylecode="italics"> <linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">P</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">harmacology (12.3)</linkhtml>]</content>
<content stylecode="italics">.</content>
</paragraph>
</item>
<item>
<paragraph>There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. </paragraph>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="underline">R</content>
<content stylecode="underline">il</content>
<content stylecode="underline">p</content>
<content stylecode="underline">i</content>
<content stylecode="underline">v</content>
<content stylecode="underline">i</content>
<content stylecode="underline">rine-containing products: </content>Concomitant use with Omeprazole Delayed-Release Capsules is contraindicated <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_4">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_4">o</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_ac7f5b5f-6981-4e8d-ac7b-8a5f46638fb0">ntraindications (4)</linkhtml>]</content>.</paragraph>
<paragraph>
<content stylecode="underline">A</content>
<content stylecode="underline">t</content>
<content stylecode="underline">azanavir: </content>Avoid concomitant use with Omeprazole Delayed-Release Capsules. See prescribing information for atazanavir for dosing information.</paragraph>
<paragraph>
<content stylecode="underline">N</content>
<content stylecode="underline">elfinavir: </content>Avoid concomitant use with Omeprazole Delayed-Release Capsules. See prescribing information for nelfinavir.</paragraph>
<paragraph>
<content stylecode="underline">S</content>
<content stylecode="underline">aquinavir: </content>See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities.</paragraph>
<content stylecode="underline">Other antiretrovirals: </content>See prescribing information for specific antiretroviral drugs. </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Warfarin</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Methotrexate</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_5_11">W</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_59531880-9076-4826-b486-1e23587115cf">arnings and Precautions (5.11)</linkhtml>].</content> </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">A temporary withdrawal of Omeprazole Delayed-Release Capsules may be considered in some patients receiving high-dose methotrexate. </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam)</content> </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Clopidogrel</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">li</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">cal</linkhtml>
</content>
<content stylecode="italics"> <linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">P</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">harmacology (12.3)</linkhtml>]</content>
<content stylecode="italics">.</content>
</paragraph> There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel<content stylecode="italics">.</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Avoid concomitant use with Omeprazole Delayed-Release Capsules. Consider use of alternative anti-platelet therapy</paragraph>
<content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_5_6">W</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_46fba6fc-1fb2-40b6-b9c9-9bbc906e566b">arnings and Precautions (5.6)</linkhtml>].</content> </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Citalopram</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Increased exposure of citalopram leading to an increased risk of QT prolongation <content stylecode="italics">[</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">see</linkhtml>
</content> <content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">li</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">cal Pharmacology (12.3)</linkhtml>]</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing  information for citalopram. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Cilostazol</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">l</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">nical Pharmacology (12.3)</linkhtml>].</content> </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Phenytoin</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Potential for increased exposure of phenytoin. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Diazepam</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Increased exposure of diazepam <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">l</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">nical Pharmacology (12.3)</linkhtml>]</content>. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content>  </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Monitor patients for increased sedation and reduce the dose of diazepam as needed. </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Digoxin</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Potential for increased exposure of digoxin <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">l</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">c</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">al Pharmacology (12.3)</linkhtml>].</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations.  See digoxin prescribing information. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<paragraph>
<content stylecode="bold">D</content>
<content stylecode="bold">rugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, </content>
<content stylecode="bold">mycophenolate mofetil, ketoconazole/itraconazole)</content> </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Omeprazole can reduce the absorption of other drugs due to its effect on reducing</paragraph> intragastric acidity. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving Omeprazole Delayed-Release Capsules and MMF. Use Omeprazole Delayed-Release Capsules with caution in transplant patients receiving MMF <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">l</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark47">nical</linkhtml>
</content>
<content stylecode="italics"> <linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">P</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">harmacology (12.3)</linkhtml>]</content>.</paragraph> See the prescribing information for other drugs dependent on gastric pH for absorption. </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="bold">Combination Therapy with Clarithromycin and Amoxicillin</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated.</paragraph> Amoxicillin also has drug interactions. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>See <content stylecode="italics">Contraindications, Warnings </content>and <content stylecode="italics">Precautions </content>in prescribing information for clarithromycin.</paragraph>
<paragraph> See <content stylecode="italics">Drug Interactions </content>in prescribing information for amoxicillin. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="bold">Tacrolimus</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19<content stylecode="italics">.</content> </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="bold">Interactions with Investigations of Neuroendocrine Tumors</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_5_10">W</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_047bd38a-a85b-478a-a70b-b79f01c3001e">arnings and Precautions (5.10)</linkhtml>
<linkhtml href="#CIA74312L%20(redlines).docx#section_5_10">, </linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark45">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark45">li</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark45">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark45">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark45">cal</linkhtml>
</content> <content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_2">P</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_e61522bf-64d9-44df-b547-ad47f74bfe43">harmacology (12.2)</linkhtml>]</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Temporarily stop Omeprazole Delayed-Release Capsules treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="bold">Interaction with Secretin Stimulation Test</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Temporarily stop Omeprazole Delayed-Release Capsules treatment at least 14 days before assessing to allow gastrin levels to return to baseline <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_2">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_2">li</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_2">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_2">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_e61522bf-64d9-44df-b547-ad47f74bfe43">cal Pharmacology (12.2)</linkhtml>]</content>. </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="bold">False Positive Urine Tests for THC</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">An alternative confirmatory method should be considered to verify positive results. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="bold">Other</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with Omeprazole Delayed-Release Capsules. </td>
</tr>
</tbody>
</table>